MetaCap

Alumis (ALMS) vs Crescent Biopharma (CBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Crescent Biopharma (CBIO) has outperformed Alumis (ALMS) over the past year, losing 0.5% versus a loss of 45.8%. Crescent Biopharma is the larger company by market cap ($543.2 million vs $514.1 million), about 1.1 times the size. Alumis converts more of its revenue into profit, with a net margin of -1011.7% versus -1419.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALMS-45.75%CBIO-0.46%
+333%+135%-64%
Nov 21, 20251 yearNov 20, 2026
ALMS-70.23%CBIO-53.57%
+133%+22%-89%
Jun 24, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALMS versus CBIO key metrics
MetricALMSCBIO
Share price$3.96$13.00
Market cap$514.09M$543.21M
1-day change-8.55%+0.70%
YTD return-59.43%+9.61%
1-year return-45.75%-0.46%
5-year return—-92.74%
EPS (TTM)$-3.53$-7.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$24.05M$10.84M
Net income (latest FY)$-243.32M$-153.94M
Operating margin-1886.92%-1407.52%
Net margin-1011.75%-1419.61%
52-week high$31.35$27.41
52-week low$3.94$8.72
Distance from 52-week high-87.37%-52.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+540.91%+148.69%
Average volume2.87M361.17K
Shares outstanding129.82M38.90M
Employees25180
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CBIO has outperformed ALMS by 45.3 percentage points over the past year.
  • Alumis is more profitable, keeping -1011.7 cents of every revenue dollar as net income versus -1419.6 cents for Crescent Biopharma.

About Alumis

ALMS stock →

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 251 employees

About Crescent Biopharma

CBIO stock →

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

ALMS vs CBIO FAQ

Which is bigger, Alumis or Crescent Biopharma?

Crescent Biopharma (CBIO) is larger, with a market capitalization of $543.21M compared with $514.09M for Alumis (ALMS).

Which stock has performed better over the past year, ALMS or CBIO?

CBIO returned -0.46% over the past 12 months, compared with -45.75% for ALMS (price return, excluding dividends). Past performance does not predict future results.

Are Alumis and Crescent Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons